Check out what we’ve been up to and where we can connect!
April 24, 2021
Results of the Adaptive COVID-19 Treatment Trial (ACTT)-2 investigating combination treatment with baricitinib, a Janus kinase inhibitor, and remdesivir for the treatment of COVID-19 in hospitalized adults were published in the New England Journal of Medicine (NEJM) on March 4, 2021, showing that the combination treatment was superior to remdesivir alone.
March 29, 2021
Phase I/II studies to evaluate human placental hematopoietic stem cell–derived natural killer (NK) cell therapy to treat COVID-19 in hospitalized adults are currently ongoing as part of our partnership with the Infectious Disease Research Institute (IDRI).
February 8, 2021
In a recent podcast discussion with TrialSite News, Claudia Christian, Senior Vice President, Clinical Operations at FHI Clinical, shares how the company’s experience in complex clinical research in resource-limited settings helps to ensure health equity and get life-saving vaccines to those who need them most.
November 20, 2020
The U.S. FDA granted emergency use authorization (EUA) for the use of baricitinib in combination with remdesivir to treat COVID-19 in hospitalized adults and children at least two years of age requiring supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation.
February 7-10, 2022
Attending SCOPE? Learn more about how we ensure best-fit sites with the most appropriate capabilities and patient populations tailored to your study protocol. Contact us to set aside time to review your feasibility and study start-up needs.
November 30 – December 2, 2021
Attending the World Vaccine and Immunotherapy Congress West Coast? Schedule a meeting with an FHI Clinical team member who will be in attendance at the event.
November 17-21, 2021
Attending the ASTMH 2021 Annual Meeting? Schedule a meeting with an FHI Clinical team member who will be in attendance at the event or stop by one of our poster presentations.
October 1-2, 2021
Attending the Global Site Solutions Summit? Schedule a time to chat with our team who will also be in attendance.
October 4-6, 2021
Attending the Maryland Life Sciences Bio Innovation Conference? Schedule some time with our team and attend the panel discussion with our Scientific Advisory Expert, Dr. Stephen Thomas.
September 27, 2021
In this webcast we will explore the intended purpose of ICH regulations; what organizations stand to gain from adopting the updated guidelines; how organizations can improve their operational efficiencies by minimizing duplicate quality-assurance steps; strategies for quick, relatively straightforward adoption of the new guidelines.
FHI Clinical Headquarters
359 Blackwell Street, Suite 200
Durham, NC 27701 USA